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Abstract Recombinant coagulation factor VII (FVII)
is used as a potential therapeutic intervention in
hemophilia patients who produce antibodies against
the coagulation factors. Mammalian cell lines provide
low levels of expression, however, the Spodoptera
frugiperda Sf9 cell line and baculovirus expression
system are powerful systems for high-level expres-
sion of recombinant proteins, but due to the lack
of endogenous vitamin K-dependent carboxylase,
expression of functional FVII using this system is
impossible. In the present study, we report a simple but
versatile method to overcome the defect for high-level
expression of the functional recombinant coagulation
FVII in Sf9 cells. This method involves simultaneous
expression of both human c-carboxylase (hGC) and
human FVII genes in the host. It may be possible to
express other vitaminK-dependent coagulation factors
using this method in the future.
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Introduction
Bleeding and hemostatic problems in hemophilia A
and B diseases can be treated with purified factor VIII
and IX preparations obtained from plasma or produced
by recombinant DNA technology. However, because
of the generation of neutralizing antibodies against
these factors which makes the management of bleed-
ing episodes difficult in such patients, it is important to
establish new treatment strategies (Shapiro et al.
1998).
Thus far, therapeutic interventions in these situa-
tions have included overcoming the inhibitors with
large doses of factor VIII; however, this is only
feasible when the inhibitor titer is relatively low
(Maick 1993; Nillson et al. 1993). Other approaches
have included the use of activated and non-activated
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